As of November 14, 2026, bioAffinity Technologies, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 6, 2026 (Form 8-K, March 6, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like bioAffinity Technologies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
bioAffinity Technologies, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-06. Every row below is cited to the filing it comes from, and this page adds each new change as bioAffinity Technologies, Inc. files it.
Also on the record for bioAffinity Technologies, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 18, 2026 | IPO filing, Form 424B4 | $0.8 a share | IPO filings | Source |
| June 16, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| June 12, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| April 30, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| October 1, 2025 | Stake report, Schedule 13G, by Bigger Michael | 5.79% of the class | 5%+ stakes | Source |
| September 30, 2025 | IPO filing, Form 424B4 | — | IPO filings | Source |
| September 25, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| September 24, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| September 15, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| August 29, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| May 7, 2025 | IPO filing, Form 424B4 | — | IPO filings | Source |
| May 5, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
Selling to them or working with them? See who runs bioAffinity Technologies, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on bioAffinity Technologies, Inc. and the records around it.
bioAffinity Technologies, Inc. elsewhere on the record
- IPO filing Jun 2026
- 5%+ stake filings Oct 2025
- Who owns it
Companies that share a holder
- BIGGER CAPITAL FUND L P also filed stake reports on 13 other companies: Neuraxis, INC (Nov 2026), ClearPoint Neuro, Inc. (Nov 2026), Dermata Therapeutics, Inc. (Nov 2026)
Watch bioAffinity Technologies, Inc.
Get an email when bioAffinity Technologies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on bioAffinity Technologies, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on bioAffinity Technologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on bioAffinity Technologies, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 16 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-06 | Reported | not named in the filing | 8-K, 2026-03-06 |
New leaders reset buying decisions — get the Full Report on bioAffinity Technologies, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at bioAffinity Technologies, Inc., with the record behind each one.
Find candidates like senior executive at bioAffinity Technologies, Inc.Every change, in the filing's words
Reported
On March 5, 2026, Robert Anderson and Roby Joyce informed the Board of Directors (the "Board") of bioAffinity Technologies, Inc., a Delaware corporation (the "Company"), of their decisions not to stand for re-election to the Board upon expiration of their current terms, which expire at the Company's 2026 Annual Meeting of Stockholders, currently scheduled for April 30, 2026 (the "Annual Meeting").
- Mr. Anderson's and Mr. Joyce's decisions not to stand for re-election at the Annual Meeting did not result from any disagreements with the Company on any matter relating to the Company's operations, policies or practices.
Tools for this story
Each opens in a new tab, filled in for bioAffinity Technologies, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
